Axsome Therapeutics Executive and Leadership Team

Herriot Tabuteau, the Chief Executive Officer at Axsome Therapeutics, directs the company's overarching strategy and vision. This leadership role focuses on advancing novel therapies for central nervous system (CNS) conditions that currently lack sufficient treatment options. Tabuteau guides the organization's commitment to transforming the approach to treating CNS disorders through the development of therapeutic options with unique mechanisms of action. The Chief Executive Officer ensures that product development aligns with the mission to meaningfully improve patient lives and provide physicians with additional therapeutic choices. Overseeing all corporate functions, Herriot Tabuteau drives the strategic execution necessary to achieve these critical objectives and solidify Axsome Therapeutics' market position in biopharmaceuticals.

Nicholas Pizzie, the Chief Financial Officer at Axsome Therapeutics, manages all financial operations and strategic financial planning. This executive oversees the fiscal health of the company, ensuring robust financial controls and driving capital allocation to support the development of novel therapies for central nervous system (CNS) conditions. Pizzie's responsibilities include financial reporting, investor relations, and managing the company's financial resources to facilitate the advancement of therapeutic options with unique mechanisms of action. The Chief Financial Officer plays a crucial part in enabling Axsome Therapeutics' mission to transform the approach to treating CNS disorders. By maintaining financial discipline and strategic investment, Nicholas Pizzie directly supports the goal of meaningfully improving patient lives and providing physicians with expanded therapeutic choices.

Mark Jacobson, the Chief Operating Officer at Axsome Therapeutics, oversees the operational execution of the company's strategic initiatives. This leadership position focuses on streamlining internal processes and ensuring the efficient development and delivery of novel therapies for central nervous system (CNS) conditions. Jacobson manages the day-to-day operations, driving the implementation of therapeutic options with unique mechanisms of action. The Chief Operating Officer ensures that Axsome Therapeutics' operational framework supports the company's mission to transform the approach to treating CNS disorders. By optimizing operational efficiency, Mark Jacobson directly contributes to the goal of meaningfully improving patient lives and providing physicians with additional therapeutic choices, solidifying the company's biopharmaceutical capabilities.

Shelly Ogiste, the Senior President, Vice , Quality at Axsome Therapeutics, directs the company's quality assurance and regulatory compliance functions. This executive ensures that all therapeutic options for central nervous system (CNS) conditions meet the highest standards of safety and efficacy, aligning with the company's mission to transform the approach to treating these disorders. Ogiste's oversight is critical for developing novel therapies with unique mechanisms of action, guaranteeing adherence to stringent regulatory requirements. The Senior President, Vice , Quality is instrumental in maintaining the integrity of Axsome Therapeutics' product pipeline. By upholding rigorous quality standards, Shelly Ogiste directly supports the objective of meaningfully improving patient lives and providing physicians with reliable therapeutic choices.